BIOMAT Database Logo BIOMAT Database Logo

Optimization of treatment in Turner's syndrome. 2004

R Gracia Bouthelier, and A Oliver Iguacel, and Isabel Gonzalez Casado, and A Alcalde de Alvaré
Endocrinología Pediátrica, Hospital Infantil La Paz, Madrid, Spain.

We discuss treatment for short stature and hypogonadism in patients with Turner's syndrome, using recombinant human growth hormone (GH) and estrogen. We discuss the starting dose of GH, age at start of treatment, and association with oxandrolone or low dose estrogen therapy before 12 years old. We provide recommendations for optimization of therapy for best final height and induction of puberty with estrogen therapy. Our experience in the Children's Endocrinology Clinic in "La Paz" University Hospital, Madrid, is that 83% of our patients need estrogen therapy and only 17% had spontaneous menarche. The average age for puberty induction was 12.2 years, and the average duration of estrogen treatment was 2.1 years. The average final height obtained using GH treatment was 151.3 cm with a gain related to predicted height of 6.8 cm.

UI MeSH Term Description Entries
D010074 Oxandrolone A synthetic hormone with anabolic and androgenic properties. Anavar,Oxandrin,SC-11585,SC 11585,SC11585
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013006 Growth Hormone A polypeptide that is secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized. Growth Hormone, Recombinant,Pituitary Growth Hormone,Recombinant Growth Hormone,Somatotropin,Somatotropin, Recombinant,Growth Hormone, Pituitary,Growth Hormones Pituitary, Recombinant,Pituitary Growth Hormones, Recombinant,Recombinant Growth Hormones,Recombinant Pituitary Growth Hormones,Recombinant Somatotropins,Somatotropins, Recombinant,Growth Hormones, Recombinant,Recombinant Somatotropin
D014424 Turner Syndrome A syndrome of defective gonadal development in phenotypic females associated with the karyotype 45,X (or 45,XO). Patients generally are of short stature with undifferentiated GONADS (streak gonads), SEXUAL INFANTILISM, HYPOGONADISM, webbing of the neck, cubitus valgus, elevated GONADOTROPINS, decreased ESTRADIOL level in blood, and CONGENITAL HEART DEFECTS. NOONAN SYNDROME (also called Pseudo-Turner Syndrome and Male Turner Syndrome) resembles this disorder; however, it occurs in males and females with a normal karyotype and is inherited as an autosomal dominant. Bonnevie-Ullrich Syndrome,Gonadal Dysgenesis, 45,X,Gonadal Dysgenesis, XO,Monosomy X,Status Bonnevie-Ullrich,Turner's Syndrome,Ullrich-Turner Syndrome,Bonnevie Ullrich Syndrome,Status Bonnevie Ullrich,Syndrome, Ullrich-Turner,Turners Syndrome,Ullrich Turner Syndrome,XO Gonadal Dysgenesis
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

R Gracia Bouthelier, and A Oliver Iguacel, and Isabel Gonzalez Casado, and A Alcalde de Alvaré
Treatment of Turner's syndrome.
December 1996, Lancet (London, England),
R Gracia Bouthelier, and A Oliver Iguacel, and Isabel Gonzalez Casado, and A Alcalde de Alvaré
Growth hormone treatment in Turner's syndrome.
January 1986, Acta paediatrica Scandinavica. Supplement,
R Gracia Bouthelier, and A Oliver Iguacel, and Isabel Gonzalez Casado, and A Alcalde de Alvaré
Proceedings: Hormonal treatment of Turner's syndrome.
January 1975, Acta paediatrica Scandinavica. Supplement,
R Gracia Bouthelier, and A Oliver Iguacel, and Isabel Gonzalez Casado, and A Alcalde de Alvaré
Treatment of Turner's syndrome--a concern.
September 1996, Lancet (London, England),
R Gracia Bouthelier, and A Oliver Iguacel, and Isabel Gonzalez Casado, and A Alcalde de Alvaré
Treatment of Turner's syndrome with estrogen.
December 1978, Pediatrics,
R Gracia Bouthelier, and A Oliver Iguacel, and Isabel Gonzalez Casado, and A Alcalde de Alvaré
Sevesevskij-Turner's syndrome or Turner's syndrome.
October 1977, Human genetics,
R Gracia Bouthelier, and A Oliver Iguacel, and Isabel Gonzalez Casado, and A Alcalde de Alvaré
Turner's syndrome and pseudo-Turner's syndrome.
May 1967, The American journal of roentgenology, radium therapy, and nuclear medicine,
R Gracia Bouthelier, and A Oliver Iguacel, and Isabel Gonzalez Casado, and A Alcalde de Alvaré
Turner's syndrome, twenty years after treatment.
September 1957, The Medical journal of Australia,
R Gracia Bouthelier, and A Oliver Iguacel, and Isabel Gonzalez Casado, and A Alcalde de Alvaré
Value of growth hormone treatment in Turner's syndrome.
April 2000, Endocrine,
R Gracia Bouthelier, and A Oliver Iguacel, and Isabel Gonzalez Casado, and A Alcalde de Alvaré
[Treatment of dwarfism in Turner's syndrome (ovarian dysgenesis)].
October 1966, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
Copied contents to your clipboard!